Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza A viruses by single-nucleotide polymorphism analysis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4718-4727

  Duan, Susu ^a,b   Boltz, David A ^a,c   Li, Jiang ^a   Oshansky, Christine M ^a   Marjuki, Henju ^a   Barman, Subrata ^a   Webby, Richard J ^a   Webster, Robert G ^a,b   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c IIT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIALIDASE INHIBITOR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BACTERIOPHAGE; CLINICAL ASSESSMENT; EPITHELIUM CELL; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASONAL INFLUENZA; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INFECTION;

ANTIVIRAL AGENTS; BASE SEQUENCE; DNA PROBES; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; EPITHELIAL CELLS; GENOTYPE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; NEURAMINIDASE; OSELTAMIVIR; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS; ZANAMIVIR;

EID: 80052834610     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00316-11     Document Type: Article

References (41)

1. Abed, Y., M. Baz, and G. Boivin. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir. Ther. 11:971-976.
2. Bautista, E., et al. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362:1708-1719.
3. Birnkrant, D., and E. Cox. 2009. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 361:2204-2207.
4. Budowle, S. A., S. Gonzalez, B. Budowle, A. J. Eisenberg, and R. W. Grange. 2008. A novel SNaPshot assay to detect the mdx mutation. Muscle Nerve 37:731-735.
5. Deyde, V. M., et al. 2009. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrob. Agents Chemother. 53:1039-1047.
6. Deyde, V. M., et al. 2009. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res. 81:16-24.
7. Deyde, V. M., et al. 2010. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob. Agents Chemother. 54:1102-1110.
8. Duan, S., et al. 2010. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog. 6:e1001022.
9. Duwe, S., and B. Schweiger. 2008. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 153:134-141.
10. Gubareva, L. V., et al. 2010. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir. Ther. 15:1151-1159.
11. Guo, L., et al. 2009. Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antiviral Res. 82:29-33.
12. Hurst, C. D., T. C. Zuiverloon, C. Hafner, E. C. Zwarthoff, and M. A. Knowles. 2009. A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res. Notes 2:66.
13. Hurt, A. C., et al. 2011. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia- Pacific region, March 2009 to March 2010. Euro Surveill. 16(3):pii=19770.
14. Ibe, S., S. Fujisaki, S. Fujisaki, T. Morishita, and T. Kaneda. 2006. Quantitative SNP-detection method for estimating HIV-1 replicative fitness: application to protease inhibitor-resistant viruses. Microbiol. Immunol. 50:765-772.
15. Ison, M. G., L. V. Gubareva, R. L. Atmar, J. Treanor, and F. G. Hayden. 2006. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193:760-764.
16. Kiso, M., et al. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. (Pubitemid 39165094)
17. Lackenby, A., C. I. Thompson, and J. Democratis. 2008. The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 21:626-638.
18. Le, Q. M., et al. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. (Pubitemid 41509341)
19. Li, L., et al. 2011. Simultaneous detection of CYP3A5 and MDR1 polymorphisms based on the SNaPshot assay. Clin. Biochem. 44(5-6):418-422.
20. Liu, C. M., et al. 2010. Rapid quantification of single-nucleotide mutations in mixed influenza A viral populations using allele-specific mixture analysis. J. Virol. Methods 163:109-115.
21. Lou, C., et al. 2011. A SNaPshot assay for genotyping 44 individual identification single nucleotide polymorphisms. Electrophoresis 32:368-378.
22. McKimm-Breschkin, J., et al. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47:2264-2272.
23. Mehta, T., et al. 2010. Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza virus infection in immunocompromised patients: utility of cycle threshold values of qualitative real-time reverse transcriptase PCR. J. Clin. Microbiol. 48:4326-4328.
24. Moscona, A. 2005. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353:1363-1373.
25. Moscona, A. 2005. Oseltamivir resistance - disabling our influenza defenses. N. Engl. J. Med. 353:2633-2636.
26. Moscona, A. 2009. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 360:953-956.
27. Murphy, K. M., et al. 2003. A single nucleotide primer extension assay to detect the APC I1307K gene variant. J. Mol. Diagn. 5:222-226.
28. Nguyen, H. T., T. G. Sheu, V. P. Mishin, A. I. Klimov, and L. V. Gubareva. 2010. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 54:3671-3677.
29. Nukiwa, N., et al. 2010. Simplified screening method for detecting oseltamivir resistant pandemic influenza A (H1N1) 2009 virus by a RT-PCR/restriction fragment length polymorphism assay. J. Virol. Methods 170:165-168.
30. Okomo-Adhiambo, M., et al. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob. Agents Chemother. 54:1834-1841.
31. Okomo-Adhiambo, M., et al. 2010. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res. 85:381-388.
32. Operario, D. J., M. J. Moser, and K. St. George. 2010. Highly sensitive and quantitative detection of the H274Y oseltamivir resistance mutation in seasonal A/H1N1 influenza virus. J. Clin. Microbiol. 48:3517-3524.
33. Oshansky, C. M., J. P. Barber, J. Crabtree, and R. A. Tripp. 2010. Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells. J. Infect. Dis. 201:1201-1207.
34. Potier, M., L. Mameli, M. Belisle, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha- D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
35. Roberts, N. A., and E. A. Govorkova. 2009. The activity of neuraminidase inhibitor oseltamivir against all subtypes of influenza viruses, p. 93-118. In P. M. Mitrasinovic (ed.), Global view of the fight against influenza. Nova Science Publishers, Hauppauge, NY.
36. van der Vries, E., F. F. Stelma, and C. A. Boucher. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N. Engl. J. Med. 363:1381-1382.
37. Wang, B., et al. 2010. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res. 87:16-21.
38. Weinstock, D. M., and G. Zuccotti. 2009. The evolution of influenza resistance and treatment. JAMA 301:1066-1069.
39. Wetherall, N. T., et al. 2003. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41:742-750.
40. WHO. 2010. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. WHO, Geneva, Switzerland. http://www.who.int/csr/resources/publications/swineflu/h1n1-use-antivirals- 20090820/en/index.html.
41. Yen, H. L., et al. 2007. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81:12418-12426.